247 related articles for article (PubMed ID: 34660327)
1. Dual-Specificity Phosphatase 11 Is a Prognostic Biomarker of Intrahepatic Cholangiocarcinoma.
Xu L; Wang P; Zhang W; Li W; Liu T; Che X
Front Oncol; 2021; 11():757498. PubMed ID: 34660327
[TBL] [Abstract][Full Text] [Related]
2. The expression, clinical relevance, and prognostic significance of HJURP in cholangiocarcinoma.
Yang Y; Yuan J; Liu Z; Cao W; Liu P
Front Oncol; 2022; 12():972550. PubMed ID: 35965590
[TBL] [Abstract][Full Text] [Related]
3. Cholangiocarcinoma miscoding in hepatobiliary centres.
Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
[TBL] [Abstract][Full Text] [Related]
4. Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma.
Zheng Y; Qin Y; Gong W; Li H; Li B; Wang Y; Chao B; Zhao S; Liu L; Yao S; Shi J; Shi X; Wang K; Xu S
J Gastrointest Oncol; 2021 Dec; 12(6):2631-2642. PubMed ID: 35070393
[TBL] [Abstract][Full Text] [Related]
5. Aldehyde dehydrogenase 3B2 promotes the proliferation and invasion of cholangiocarcinoma by increasing Integrin Beta 1 expression.
Wang Y; Li K; Zhao W; Liu Z; Liu J; Shi A; Chen T; Mu W; Xu Y; Pan C; Zhang Z
Cell Death Dis; 2021 Dec; 12(12):1158. PubMed ID: 34907179
[TBL] [Abstract][Full Text] [Related]
6. Tumour stage and overall survival in patients with intrahepatic cholangiocarcinoma and primary sclerosing cholangitis - a retrospective cohort study.
Schramm C; Sapuk A; Hoyer D; Radünz S; Schmidt H
Z Gastroenterol; 2024 Jan; 62(1):37-42. PubMed ID: 38195106
[TBL] [Abstract][Full Text] [Related]
7. The Smad4-MYO18A-PP1A complex regulates β-catenin phosphorylation and pemigatinib resistance by inhibiting PAK1 in cholangiocarcinoma.
Liu J; Ren G; Li K; Liu Z; Wang Y; Chen T; Mu W; Yang X; Li X; Shi A; Zhao W; Xu B; Chang J; Guo S; Pan C; Zhou T; Zhang Z; Xu Y
Cell Death Differ; 2022 Apr; 29(4):818-831. PubMed ID: 34799729
[TBL] [Abstract][Full Text] [Related]
8. ZFAND5 Is an Independent Prognostic Biomarker of Perihilar Cholangiocarcinoma.
Liu P; Wang Y; Duan L
Front Oncol; 2022; 12():955670. PubMed ID: 35912230
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis, diagnosis, and management of cholangiocarcinoma.
Ilyas SI; Gores GJ
Gastroenterology; 2013 Dec; 145(6):1215-29. PubMed ID: 24140396
[TBL] [Abstract][Full Text] [Related]
10. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
Kriegsmann M; Roessler S; Kriegsmann K; Renner M; Longuespée R; Albrecht T; Loeffler M; Singer S; Mehrabi A; Vogel MN; Pathil A; Köhler B; Springfeld C; Rupp C; Weiss KH; Goeppert B
BMC Cancer; 2019 Jan; 19(1):72. PubMed ID: 30646854
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical characteristics and mortality risk between patients with cholangiocarcinoma: A retrospective cohort study.
Liu Y; Wang Y; Yu Y; Luo H; Zhen M; Ren J
Front Surg; 2022; 9():1037310. PubMed ID: 36873806
[TBL] [Abstract][Full Text] [Related]
12. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.
Izquierdo-Sanchez L; Lamarca A; La Casta A; Buettner S; Utpatel K; Klümpen HJ; Adeva J; Vogel A; Lleo A; Fabris L; Ponz-Sarvise M; Brustia R; Cardinale V; Braconi C; Vidili G; Jamieson NB; Macias RI; Jonas JP; Marzioni M; Hołówko W; Folseraas T; Kupčinskas J; Sparchez Z; Krawczyk M; Krupa Ł; Scripcariu V; Grazi GL; Landa-Magdalena A; Ijzermans JN; Evert K; Erdmann JI; López-López F; Saborowski A; Scheiter A; Santos-Laso A; Carpino G; Andersen JB; Marin JJ; Alvaro D; Bujanda L; Forner A; Valle JW; Koerkamp BG; Banales JM
J Hepatol; 2022 May; 76(5):1109-1121. PubMed ID: 35167909
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of cholangiocarcinoma.
Qurashi M; Vithayathil M; Khan SA
Eur J Surg Oncol; 2023 Sep; ():107064. PubMed ID: 37709624
[TBL] [Abstract][Full Text] [Related]
14. Annexin10 promotes extrahepatic cholangiocarcinoma metastasis by facilitating EMT via PLA2G4A/PGE2/STAT3 pathway.
Sun R; Liu Z; Qiu B; Chen T; Li Z; Zhang X; Xu Y; Zhang Z
EBioMedicine; 2019 Sep; 47():142-155. PubMed ID: 31492557
[TBL] [Abstract][Full Text] [Related]
15. Novel Targeted Therapies for Advanced Cholangiocarcinoma.
Rizzo A; Brandi G
Medicina (Kaunas); 2021 Feb; 57(3):. PubMed ID: 33652960
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapies for Perihilar Cholangiocarcinoma.
Gray S; Lamarca A; Edeline J; Klümpen HJ; Hubner RA; McNamara MG; Valle JW
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406560
[TBL] [Abstract][Full Text] [Related]
17. High Bile Titer and High Bile to Serum Ratio of CYFRA 21 - 1 Reliably Discriminate Malignant Biliary Obstruction Caused by Cholangiocarcinoma.
Chen J; Liang J; Xu B; Liang J; Ma M; Wang Z; Zeng G; Xu Q; Liang L; Lai J; Huang L
J Gastrointest Cancer; 2024 Jan; ():. PubMed ID: 38280173
[TBL] [Abstract][Full Text] [Related]
18. Emerging molecular therapeutic targets for cholangiocarcinoma.
Ilyas SI; Gores GJ
J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study.
Zhang C; You X; Zhang Q; Wang D
Invest New Drugs; 2024 Feb; 42(1):24-34. PubMed ID: 37975978
[TBL] [Abstract][Full Text] [Related]
20. The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma.
Lurje G; Bednarsch J; Czigany Z; Lurje I; Schlebusch IK; Boecker J; Meister FA; Tacke F; Roderburg C; Den Dulk M; Gaisa NT; Bruners P; Neumann UP
Eur J Surg Oncol; 2019 Aug; 45(8):1468-1478. PubMed ID: 31053477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
